ImmProCure: Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer (clinicaltrials.gov) - Oct 7, 2026 - P2 | N=84 | Recruiting | Sponsor: University Hospital Tuebingen
New P2 trial • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
|